ALEC · NASDAQ · Biotechnology

Alector (ALEC)

Develops brain-penetrant therapies for neurodegenerative disease through its ABC delivery platform.

$2.01
After hours+0.01 (+0.50%)
At close$2.00(+3.63%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue91516151554483613
Cost of revenue4622248463428293220
Gross profit−37131413−338−30−20−26−26−13
136057581615151412132428
Research & development544543445349383431281819
1315141416151514121088
General & administrative1315141416151514121088
Other expenses−54000−53−49−38−34−31−25−20
Operating income−51−47−44−46−48−7−45−34−38−40−25−24
788765443222
Other non-operating income0−8−8−7−6−5−4−4−3−2−2−2
Income before tax−43−40−36−39−42−2−40−31−35−37−23−23
Income tax expense120000000000
Net income from continuing operations−44−41−36−39−42−2−40−31−35−37−23−23
Net income−44−41−36−39−42−2−40−31−35−37−23−23
EPS, basic−$0.53−$0.49−$0.38−$0.40−$0.44−$0.02−$0.41−$0.30−$0.34−$0.34−$0.21−$0.21
EPS, diluted−$0.53−$0.49−$0.38−$0.40−$0.44−$0.02−$0.41−$0.30−$0.34−$0.34−$0.21−$0.21
Weighted average shares, basic84849497979899100103103111111
Weighted average shares, diluted84849497979899100103103111111
EBITDA−49−38−34−36−400−39−27−33−35−21−19
Depreciation & amortization122222231224
EBIT−51−40−36−39−42−2−40−31−35−37−23−23